BioLineRx COMBAT/KEYNOTE-202

BioLineRx starts triple combination arm of COMBAT/KEYNOTE-202 study

BioLineRx has commenced the triple combination arm of the Phase IIa COMBAT/KEYNOTE-202 trial of BL-8040 and keytruda (pembrolizumab) for the…